Pharmamarketeer
wet- en regelgeving

AstraZeneca’s infant respiratory drug prioritised in Europe, U.S.

6 februari 2019
Reuters Health

Britain’s AstraZeneca said a potential medicine to prevent respiratory syncytial virus (RSV) in babies and infants had been granted special status by U.S. and European regulators, designed to speed up the development of novel and better drugs.

Ook interessant voor je

Medhc-fases-banner
Advertentie(s)